Cervical cancer is caused by human papillomavirus (HPV) in collaboration with other non-viral factors. The uterine cervix is hormone responsive and female hormones have been implicated in the pathogenesis of the disease. HPV transgenic mice expressing HPV16 oncogenes E6 (K14E6) and/or E7 (K14E7) have been employed to study a mechanism of estrogen and estrogen receptor α (ERα) in cervical carcinogenesis. A chronic exposure to physiological levels of exogenous estrogen leads to cervical cancer in the HPV transgenic mice, which depends on ERα. The receptor is composed of multiple functional domains including a DNAbinding domain (DBD), which mediates its binding to estrogenresponsive elements (EREs) on target genes. A transcriptional control of genes by ERα is mediated by either DBD-dependent (classical) or DBD-independent (non-classical) pathway. Although molecular mechanisms of ERα in cancer have been characterized extensively, studies investigating importance of each pathway for carcinogenesis are scarce. In this study, we employ knock-in mice expressing an ERα DBD mutant (E207A/G208A) that is defective specifically for ERE binding. We demonstrate that the ERα DBD mutant fails to support estrogen-induced epithelial cell proliferation and carcinogenesis in the cervix of K14E7 transgenic mice. We also demonstrate that cervical diseases are absent in K14E7 mice when one ERα DBD mutant allele and one wild-type allele are present. We conclude that the ERα classical pathway is required for cervical carcinogenesis in a mouse model.
Introduction
Although cervical cancer incidence has been decreasing in developed countries, the disease remains the second most prevalent malignancy and the second leading cause of death by cancer in women in developing countries (1) . Most cervical malignancies arise in premenopausal women and are associated with high-risk human papillomavirus (HPV) (2) . Regular Pap test and HPV vaccines are effective in preventing the cancer (3) but not readily available to women in developing countries or low-income population. In addition, the current therapies for cervical cancer (i.e. surgery, chemotherapy and radiation) are not effective in treating late stage or recurrent diseases (4) . Precancer lesions [i.e. cervical intraepithelial neoplasia (CIN)] detected by Pap test can be easily removed by simple surgical procedures, thereby preventing the cancer. These surgeries, however, are associated with adverse outcomes in future pregnancy, including preterm birth and infant morbidity (5) . A better understanding of cervical cancer pathogenesis is needed to develop a non-invasive method to manage the cancer and CIN more effectively.
A subset of >100 HPV types is causally associated with various human cancers including those in the uterine cervix (2) . They are called high-risk HPVs and transmitted mainly by sexual contacts. Most commonly found in cancers is HPV16 followed by HPV18, both of which are commonly targeted by current prophylactic HPV vaccines (3) . These two types account only for 70-80% of all cervical cancers and thus those vaccines have little impact on the remainder. High-risk HPVs code for E6 and E7 oncogenes and numerous studies have proved their potent oncogenic activities in vitro and in vivo (2, 6) . The tumorigenic potential of these viral oncoproteins depends on their ability to interact with various cellular proteins regulating cancer-associated cellular processes such as apoptosis and cell cycle (2) . Most notably, E6 promotes degradation of a key apoptosis regulator p53 and E7 inactivates a cell cycle regulator pRb. E6 and E7 are required not only for the development of cervical cancer but also for its continued growth (7) (8) (9) . Evidence also suggests that HPV is not sufficient to cause cervical cancer and other HPV-associated malignancies (6, 10) .
Several lines of epidemiological evidence implicate female hormones (e.g. estrogen) in HPV-associated cervical cancer (10, 11) . Consistently, estrogen is required for cervical cancer to develop in HPV transgenic mice (12, 13) . Cervical disease occurring in those mice is progressive and preferentially arises in the transformation zone, which mimics human cervical cancer (12) . It also shows the expression pattern of biomarkers similar to that of the human cancer (14) . Estrogen receptor α (ERα) is necessary for the development and continued growth of cervical cancer in the same mouse model but not for HPV oncogene functions (15, 16) . ERα is also crucial for estrogeninduced cell proliferation in the normal cervical epithelium (16) .
ERα is a transcription factor and composed of multiple functional domains, activation function 1 domain, DNA-binding domain (DBD) and ligand-binding domain encompassing activation function 2 domain. In the classical pathway, the DBD is responsible for direct binding of ERα to estrogen-responsive elements (EREs) on its target genes, thereby regulating their transcription (17) . In non-classical or tethering pathway, ERα indirectly binds DNA through interactions with other transcription factors such as AP1 and Sp1. Physiological importance of the ERα classical pathway in estrogen-responsive tissues such as uterus and bone has been demonstrated by studies using a knock-in mouse model, which expresses an ERα DBD mutant (E207A/G208A) defective for binding EREs (i.e. deficient for the classical pathway) (18) (19) (20) . Using the same knock-in mice, we here report that the ERα DBD is required for estrogen-dependent cervical carcinogenesis in the K14E7 transgenic mouse model. Our results support that the ERα classical pathway is crucial for estrogen-dependent cervical cancer in vivo.
Materials and methods

Mice and treatments
Mice used in this study were described previously (18, (21) (22) (23) (24) and summarized in Supplementary Table SI, available at Carcinogenesis Online. All mice were genotyped by PCR. Some mice were ovariectomized at the age of 6-8 weeks and recovered for 2 weeks. They were then intraperitoneally injected with ethanol vehicle or 17β-estradiol (E 2 ; 1 μg) for 7 days. For longer E 2 treatments, slow-releasing E 2 tablets (0.05 mg/60 days) (Innovative Research of America, Sarasota, FL) were subcutaneously inserted under the dorsal skin every 2 months as described previously (25) . Subsets of mice were intraperitoneally injected with bromo-deoxyuridine (BrdU) (3.75 mg J.Son et al.
per mouse) 1 h prior to killing to measure cell proliferation. All procedures were carried out according to animal protocols approved by the University of Houston Institutional Animal Care and Use Committee and the University of Wisconsin School of Medicine and Public Health Institutional Animal Care and Use Committee.
Tissue processing and histology
The female reproductive tracts were harvested, fixed in 4% paraformaldehyde and embedded in paraffin. The tissues were serially sectioned throughout cervices at 5 μm thickness. Every 10th slide was stained with hematoxylin and eosin and the worst disease was determined as described previously (13, 14) .
Immunohistochemistry
Antibodies were purchased from Santa Cruz Biotechnology [ERα (H184), progesterone receptor (PR) (H190) and p16], Calbiochem (BrdU), Neomarkers (MCM7), Thermo Scientific (Ki67) and Rockland Immunochemicals (biotinylated anti-rabbit/mouse IgG). For Ki67 immunohistochemistry, sections were sequentially incubated with anti-Ki67 antibody (1:200 in 5% goat serum in phosphate-buffered saline) and biotinylated anti-rabbit IgG, and then with ABC complex (Vector Laboratories) according to the manufacturer's instructions. The immune complex was visualized by an incubation in 3,3′-diaminobenzidine (Sigma) dissolved in phosphate-buffered saline (0.5 mg/ml). Immunohistochemistry for MCM7, PR, p16, ERα and BrdU was performed as described previously (14, 26, 27) . mice were similarly hypoplastic ( Figure 1A ). The treatment with E 2 resulted in physiologic hyperplasia in the cervical epithelium of ERα +/− but not ERα N/− mice ( Figure 1A) . Consistently, compared with vehicle control, number of BrdU-positive cervical epithelial cells was significantly increased upon E 2 treatment in ERα +/− but not in ERα N/− mice ( Figure 1B and C). We observed similar results in the vaginal epithelium ( Figure 1D and E). ERα expression was predominant in the nuclei of cervical stromal and epithelial cells regardless of E 2 treatment, which was similar in ERα +/− and ERα N/− mice ( Figure 1F ). These results demonstrate that the classical pathway of ERα (i.e. ERE binding) is required for E 2 -induced epithelial cell proliferation and thickening of epithelia in the lower reproductive tract of female mice.
Statistical analyses
A functional ERα DBD is required for early stage of cervical carcinogenesis in K14E7 mice
The phenotypes in ERα N/− mice described above were reminiscent of those observed in ERα −/− mice (16). We therefore hypothesized (Table I) . Although difference in cancer incidence did not reach statistical significance (P = 0.08), overall cervical disease severity was significantly worse in K14E7/ERα +/− mice compared with K14E7/ ERα N/− mice (P = 6.91 × 10 −6 ). It was also evident that the cervical epithelia of K14E7/ERα N/− mice were hypoplastic as opposed to the hyperplastic epithelia in K14E7/ER +/− control mice (Figure 2A ). Consistently, a fraction of Ki67-positive cells (i.e. proliferating cells) was dramatically diminished in K14E7/ERα N/− mice compared with K14E7/ERα +/− control mice ( Figure 2B and C). Atypical squamous metaplasia (ASM) in the cervical transformation zone is believed to be the first step in cervical carcinogenesis and ERα is required for its development (16 were not significantly different ( Figure 3A and B), indicating that the classical pathway of wt ERα was not inhibited in those heterozygotic mice. Induction of suprabasal cell proliferation is one of the hallmarks for E7 function in the squamous epithelium (25) . Suprabasal cell proliferation was dramatically increased in K14E7/ERα +/f mice compared with NTG/ERα +/f mice (2.3 ± 0.5 versus 0.4 ± 0.3%, P = 0.02); it was similarly increased in K14E7/ERα N/f mice compared with NTG/ ERα N/f mice (1.3 ± 0.2 versus 0.4 ± 0.1%, P = 0.02) ( Figure 3A and B . We treated them with E 2 for 6 months and anticipated that all genotypes would similarly develop cervical diseases based on results shown in Figure 3 as well as previously published results (26) Figure S1 , available at Carcinogenesis Online). Consequently, we were unable to evaluate whether the ERα classical pathway is required for later stages of cervical carcinogenesis. It should be mentioned that genotypes were pooled based on ERα status regardless of CMVCreER status because CMVCreER transgene did not affect disease severity in this study (data not shown) similarly to previously published results (26) and none of the mice were treated with tamoxifen. Cervical cancer incidence in K14E7/ERα +/f mice was similar to K14E7/ERα +/− mice (P = 0.29), confirming haplosufficiency of ERα. Vaginal diseases were also absent in K14E7/ERα N/f mice, which was significantly different from K14E7/ERα +/f mice (P = 2.28 × 10 −10
; Table I ). Figure 4A  and B) . This was surprising because we did not observe such defects in the same mice treated with E 2 for 4 weeks (see Figure 3) . Ages of mice at the endpoints were 2.5 months for those treated for 4 weeks in Figure 3 and 7.5 months for those treated for 6 months. To determine if the difference in phenotypes was due to age of mice, we generated NTG/ERα
Long-term but not short-term E 2 treatment results in defects in
, K14E7/ERα +/f and K14E7/ERα N/f mice and treated them for 4 weeks with E 2 at 6.5 months of age (7.5-monthold at killing). Basal cell proliferation was similar in all genotypes ( Figure 4C and D Figure 4C and D) . These results were similar to those shown in Figure 3 , indicating that K14E7/ERα N/f mice respond similarly to 4-week long E 2 treatment regardless of their age. Basal and suprabasal cell proliferations were significantly decreased in K14E7/ERα N/f mice treated for 6 months compared with age-matched mice treated for 4 weeks (P < 0.05) ( Figure 4B and D) . We conclude that K14E7/ERα N/f mice have altered response to long-term (e.g. 6 months) treatment with E 2 .
HPV oncogenes and ERα classical pathway are active in cervices of K14E7/ERα
N/f mice treated with E 2 for 6 months One possibility for the lack of cervical disease in K14E7/ERα N/f mice was that a function of E7 was inhibited. We, however, found that MCM7 and p16, surrogate markers for E7 function (28), were highly expressed in the cervical epithelium of K14E7/ERα N/f mice similar to K14E7/ERα +/f control mice ( Figure 5A ). These results are consistent with the fact that E7 expression and MCM7 upregulation are independent of ERα status (16) . Another possibility was that the mutant ERα blocked ERE binding of wt ERα when treated with E 2 for 6 months but not for 4 weeks (see Figure 3) . We used PR as a marker for ERα classical pathway because PR was not expressed in ERα N/− cervix treated with E 2 (Supplementary Figure S2 , available at Carcinogenesis Online). PR expression was evident in cervical epithelia and stroma of all K14E7/ERα +/f control mice and 10 out of 13 K14E7/ERα N/f mice ( Figure 5B ). Interestingly, 3 of 13 cervical tissues showed strong PR staining in the stroma but not in the epithelia ( Figure 5B ). Subcellular localization of ERα was not altered in K14E7/ERα N/f cervices; the majority of ERα was present in the nucleus regardless of ERα genotype ( Figure 5B ). These results indicate that the ERα mutant did not grossly inhibit wt ERα in K14E7/ ERα N/f cervices when treated for 6 months with E 2 .
Discussion
Molecular mechanisms by which ERα promotes estrogen-dependent cancers such as breast cancer have been extensively studied. Although many studies have focused on how ERα binds to DNA and how coregulators modulate transcription of ERα target genes (29) , only few studies have evaluated whether ERE binding is crucial for growth of breast cancer cells (30, 31) . Our present study demonstrated that K14E7/ERα N/− mice were resistant to the development of ASM, the earliest stage of cervical neoplasia ( Figure 2D ), indicating that the ERα classical pathway is necessary for initiation of cervical cancer. We speculate that ERE binding may be also crucial for progression and/or persistence of cervical cancer because the ERα classical pathway is associated with proliferation of breast cancer cells (30, 31) .
Potential ERα target genes that are crucial for cervical carcinogenesis and regulated by the classical pathway
A plethora of genes are either upregulated or downregulated by ERα, many of which are involved in regulation of cell cycle, apoptosis and migration (32) . ERα expression inhibits the invasive potential of human cervical cancer cells in vitro (33) . ERα is often lost in human cervical cancer but expressed in surrounding stroma (34) . Deletion of stromal ERα ablates cervical neoplasia in the K14E7 transgenic mice (26) . These observations put forth the hypothesis that stromal ERα promotes but epithelial ERα suppresses cervical cancer. It is conceivable that ERα-dependent paracrine factor(s) secreted by stromal cells may promote cervical carcinogenesis. If these were correct, regulation of paracrine factors by ERα is likely independent of HPV oncogenes because cervical stromal cells do not express them in these mice (13) . Estrogen upregulates genes coding for such factors including insulinlike growth factor 1 (IGF1), fibroblast growth factors (FGFs) and Wnt ligands. Transcriptional regulation of Igf1 by estrogen requires direct binding of ERα to EREs (35) . IGF1 promotes proliferation of cervical cancer cells and IGF1 receptor is required for their growth in soft agar (36) . Fgf2 and Fgf9 are upregulated by estrogen and contain consensus EREs upstream of transcription start site (37) . Fgf10 also contains an ERE, of which location and sequence are conserved in human and mouse (37) . Activation of FGFR2 IIIb (receptor for FGF10) or FGFR2 IIIc (receptor for FGF2 and FGF9) promotes proliferation of human cervical cancer cells (38, 39) . Genes coding for several Wnt ligands (e.g. WNT1, WNT2B, WNT4, WNT10B) also contain consensus EREs (37). Overexpression of constitutively active β-catenin (downstream of Wnt signaling) augments cervical carcinogenesis in K14E7 mice (40) .
Potential mechanisms by which the ERα DBD mutant inhibits cervical carcinogenesis
It was surprising that cervical disease did not arise in K14E7/ERα N/f mice because, in the absence of Cre activity, they possessed an allele that expresses wt ERα. It is intriguing to note that enhanced eosin staining (presumably representing collagens and other acidic extracellular matrix proteins) in cervical stroma of K14E7/ERα N/f mice (Supplementary Figure S1 , available at Carcinogenesis Online) was also observed in mice treated with fulvestrant or raloxifene (15) . These selective ER modulators are efficient in treating cervical cancer in HPV transgenic mice (15) . One possibility for the lack of cervical disease in K14E7/ERα N/f mice is that the mutant ERα predominantly forms heterodimer with wt ERα and thus inhibits its binding to EREs. Such a dominant-negative effect of the mutant, however, does not appear to be significantly at play because PR expression, which depends on ERα DBD function (Supplementary Figure S2 , available at Carcinogenesis Online), was retained in the cervix of most K14E7/ ERα N/f mice ( Figure 5B ). In addition, the E207A/G208A mutant does not inhibit expression of an ERE-dependent reporter gene even when overexpressed 10 times more than wt ERα (18) . Nonetheless, the fact that PR expression was absent in cervical epithelial cells of three K14E7/ERα N/f mice ( Figure 5B ) suggests that a dominant-negative effect may arise in some contexts. Another possibility is that the mutant ERα results in epigenetic changes in, at least, a subset of classical pathway target genes necessary for cancer promotion. We would argue that such an epigenetic effect becomes more pronounced over time because significant impact on cell proliferation was observed after 6-month E 2 treatment but not after 4-week treatment in K14E7/ ERα N/f mice (Figure 4) . The third possibility is that a balance between classical (i.e. ERE binding) and non-classical pathway (i.e. interaction with other transcription factors such as AP1 and Sp1) is important for cervical carcinogenesis. We favor this possibility because the mutant ERα (E207A/G208A) used in this study activates an AP1 reporter gene and non-ERE target genes (18) , and because microarray analyses have suggested that it augments non-classical activity compared with wt ERα (41) . Although a precise mechanism for inhibition of cervical carcinogenesis by the E207A/G208A mutant remains to be determined, the result further supports our conclusion that the classical pathway is necessary for cervical carcinogenesis.
A role of the classical pathway in ERα-dependent cancers
Our results are the first to show that ERα DBD is necessary for the earliest stage of cervical carcinogenesis, which we had shown previously to be ERα dependent in mice (16) . A role of ERα in cancer is best characterized in breast cancer and selective ER modulator tamoxifen is most widely used for treatment of ERα-positive breast cancer (42) . However, those cancers often develop tamoxifen resistance and tamoxifen promotes growth of those resistant tumors. Disulfide benzamide, an ER zinc finger inhibitor, restores tamoxifen sensitivity in tamoxifen-resistant breast cancer models (31) . Interestingly, it correlates to inhibition of tamoxifen-induced ERα binding to EREs but not to non-EREs, suggesting that ERE binding (i.e. classical pathway) is crucial for tamoxifen-mediated proliferation of drug-resistant breast cancer cells. C4-12 cell line cloned from MCF7 breast cancer cells does not express ERα, yet overexpression of the receptor promotes proliferation upon estrogen treatment (30) . Human ERα DBD mutant (E203A/G204A; this mutant is equivalent to mouse ERα E207A/ G208A expressed in NERKI mice) promotes proliferation of C4-12 cells; however, their proliferation is more strongly promoted by wt ERα (30) . Combined with our results, these observations support the idea that the classical pathway is crucial for growth of ERα-dependent cancers.
In summary, our results provide strong genetic evidence for the requirement of ERα DBD for initiation of cervical carcinogenesis. Our results also suggest that selective inhibition of the ERα classical pathway or preferential activation of non-classical pathway may be effective in treating cervical cancer.
Supplementary material
Supplementary Figures S1 and S2 and Table SI can be found at http:// carcin.oxfordjournals.org/
